World Conference on Lung Cancer | Conferences

Survival Benefit Seen With Frontline Tremelimumab/Durvalumab/Chemo in Some mNSCLC

August 09, 2022

The combination of tremelimumab plus durvalumab and chemotherapy in the first-line elicited survival benefit in patients with metastatic nonsquamous cell non–small cell lung cancer who harbor STK11, KEAP1, and KRAS mutations.

New Strategies Needed for Patients With NSCLC Who Progress on Chemoimmunotherapy

August 08, 2022

Patients with non–small cell lung cancer who progress after first-line chemoimmunotherapy are in need of new treatment options and strategies, according to a retrospective analysis presented at the 2022 World Conference on Lung Cancer.